Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity

Table 2 miRNA prediction of genes with significant differences between group A and groups B and C

Gene Symbol	miRNA	Score	Energe
VPS53	hsa-miR-4638-3p	193	−45.14
	hsa-miR-5096	191	−38.75
	hsa-miR-7851-3p	184	−32.95
	hsa-miR-4763-5p	183	−38.27
	hsa-miR-2110	178	−34.93
	hsa-miR-1200	176	−29.67
	hsa-miR-619-5p	175	−33.81
ITGB8	hsa-miR-4729	179	−22.78
	hsa-miR-1208	177	−26.73
	hsa-miR-1273e	176	−29.11
	hsa-miR-136-3p	175	−21.8
PHLDB2	hsa-miR-1273 g-3p	195	−43.01
PHLDB2	hsa-miR6192	175	−36.3
GPATCH2	hsa-miR-1273 g-3p	195	−41.57
GPATCH2	hsa-miR-1273a	183	−31.32
ZNF736	hsa-miR-3189-3p	175	−31.94
TTC26	hsa-miR-1273a	187	−36.01
CENPT	hsa-miR-4726-5p	175	−35.1

Note:group A: female breast cancer patients with anthracycline-induced cardiotoxicity; group B: female breast cancer patients with chemotherapy history but no cardiotoxicity; group C: female breast cancer patients with normal ejection fraction before chemotherapy. Bold font indicates that the trends of the gene in group A were opposite to those in groups B and C. Red represents up-regulation of group A genes and down-regulation of groups B and C genes; green represents down-regulation of group A genes and up-regulation of groups B and C genes
Entries in boldface font indicates that the trends of the gene in group A were opposite to those in groups B and C

ISSN: 1471-2261